The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of frailty and high-risk immuno-nutritional score with outcomes in patients with relapsed and refractory multiple myeloma treated with chimeric antigen receptor T-cells.
 
Karnav Modi
No Relationships to Disclose
 
Othman Salim Akhtar
No Relationships to Disclose
 
Mohammed Al-Jumayli
No Relationships to Disclose
 
Martine Extermann
Honoraria - OncLive Clinical Congress Consultants
Consulting or Advisory Role - Aileron Therapeutics; Alnylam
 
Margaret Booth-Jones
No Relationships to Disclose
 
Gabe De Avila
No Relationships to Disclose
 
Nathan Parker
No Relationships to Disclose
 
Omar Alexis Castaneda Puglianini
Speakers' Bureau - Adaptive Biotechnologies
 
Ariel Grajales-Cruz
Consulting or Advisory Role - Cellectar; Sanofi
Speakers' Bureau - Amgen; Sanofi
 
Rachid C. Baz
Consulting or Advisory Role - Abbvie; BMS; Janssen; Karyopharm Therapeutics; Oncopeptides; Sanofi; Shattuck Labs
Research Funding - Abbvie (Inst); BMS (Inst); Celgene (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Merck Sharp & Dohme (Inst); Sanofi (Inst); Signal Genetics (Inst); Takeda (Inst)
Other Relationship - GlaxoSmithKline
 
Brandon Jamaal Blue
No Relationships to Disclose
 
Kenneth H. Shain
Honoraria - Adaptive Biotechnologies; Bristol-Myers Squibb; Celgene; Janssen; Sanofi; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Sanofi
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Sanofi; Takeda
Research Funding - Abbvie (Inst); Karyopharm Therapeutics (Inst)
 
Melissa Alsina
Honoraria - Janssen
Consulting or Advisory Role - BMS; Janssen Oncology
Speakers' Bureau - Janssen Oncology
 
Hien Liu
No Relationships to Disclose
 
Taiga Nishihori
Research Funding - Karyopharm Therapeutics (Inst); Novartis (Inst)
 
Frederick L. Locke
Consulting or Advisory Role - A2 Biotherapeutics; Alimera Sciences; Amgen; Bluebird Bio; Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene; Calibr; Caribou Biosciences; Celgene; Cowen; Daiichi Sankyo/UCB Japan; EcoR1 Capital; Gerson Lehrman Group; Iovance Biotherapeutics; Janssen; Kite, a Gilead company; Legend Biotech; Miltenyi Biotec; Novartis; Sana Biotechnology; Takeda; Takeda; Umoja Biopharma; Umoja Biopharma
Research Funding - Alimera Sciences (Inst); Bluebird Bio (Inst); Bristol-Myers Squibb/Celgene (Inst); Kite, a Gilead company (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - CAR T Cells with Enhanced Metabolic Fitness. Serial Number: 62/939,727 (Inst); Double Mutant Survivin Vaccine. US010414810B2. (Inst); Evolutionary Dynamics of Non-Hodgkin Lymphoma CAR-T cell therapy. Serial Number: 62/879,534. (Inst); Methods of Enhancing CAR T Cell Therapies. Serial Number: 62/892,292. (Inst)
Travel, Accommodations, Expenses - A2 Biotherapeutics; Kite, a Gilead company
 
Doris K. Hansen
Consulting or Advisory Role - Bristol Myers Squibb Foundation
Research Funding - Bristol-Myers Squibb/Celgene
 
Ciara L. Freeman
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; Incyte; Janssen; ONK Therapeutics; Sanofi; Seagen
Research Funding - Janssen; Roche/Genentech; Teva